Cargando…
Aflatoxin B(1) Negatively Regulates Wnt/β-Catenin Signaling Pathway through Activating miR-33a
MicroRNAs are known to play an important role in modulating gene expression in various diseases including cancers and cardiovascular disorders, but only a few of them are associated with the pathology of aflatoxin B(1) (AFB(1)), a potent mycotoxin. Here, we discovered a novel regulatory network betw...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754916/ https://www.ncbi.nlm.nih.gov/pubmed/24015284 http://dx.doi.org/10.1371/journal.pone.0073004 |
Sumario: | MicroRNAs are known to play an important role in modulating gene expression in various diseases including cancers and cardiovascular disorders, but only a few of them are associated with the pathology of aflatoxin B(1) (AFB(1)), a potent mycotoxin. Here, we discovered a novel regulatory network between AFB(1), miR-33a and β-catenin in human carcinoma cells. The level of miR-33a was up-regulated in hepatocellular carcinoma (HCC) cells treated with AFB(1), while in the same cells causing the decrease in β-catenin expression when treated at their IC(50) values. miR-33a, specifically miR-33a-5p, was demonstrated to down-regulate the expression of β-catenin, affect the β-catenin pathway, and inhibit cell growth. Also, by employing a luciferase assay, we found that miR-33a down-regulated β-catenin by directly binding to the 3’-UTR of β-catenin. These results suggested that AFB(1) might down-regulate β-catenin by up-regulating miR-33a. This understanding opens new lines of thought in the potential role of miR-33a in the clinical therapy of cancer. |
---|